Tharimmune, Inc. (THAR) Dividend History

Company News

• Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying

  The Dow Jones index closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Tharimmune The Trade: Tharimmune, Inc. (NASDAQ: THAR) CEO Randy Milby acquired a total of 29,000 shares an average price of $0.50. To acquire these shares, it cost around $14,587. What’s Happening: Tharimmune recently announced topline data with TH104, its lead candidate for moderate-to-severe pruritus in chronic liver disease patients. What ...

  Benzinga

  Featured Companies: CATX SHFS
• Tharimmune (THAR) Up on Positive Data From Pipeline Candidate

  Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.

  Zacks Investment Research

  Featured Companies: ACAD DVAX LGND